- Original article
- Open Access
Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases
- Yun Wang†1, 2,
- Yun-Fei Yuan†1, 3,
- Hao-Cheng Lin†1, 2,
- Bin-Kui Li1, 3,
- Feng-Hua Wang1, 2,
- Zhi-Qiang Wang1, 2,
- Pei-Rong Ding1, 4,
- Gong Chen1, 4,
- Xiao-Jun Wu1, 4,
- Zhen-Hai Lu1, 4,
- Zhi-Zhong Pan1, 4,
- De-Sen Wan1, 4,
- Peng Sun1, 5,
- Shu-Mei Yan1, 5,
- Rui-Hua Xu1, 2Email author and
- Yu-Hong Li1, 2Email author
© The Author(s) 2017
- Received: 30 November 2016
- Accepted: 17 September 2017
- Published: 2 October 2017
Pathologic response is evaluated according to the extent of tumor regression and is used to estimate the efficacy of preoperative treatment. Several studies have reported the association between the pathologic response and clinical outcomes of colorectal cancer patients with liver metastases who underwent hepatectomy. However, to date, no data from Chinese patients have been reported. In this study, we aimed to evaluate the association between the pathologic response to pre-hepatectomy chemotherapy and prognosis in a cohort of Chinese patients.
Patients and methods
In this retrospective study, we analyzed the data of 380 liver metastases in 159 patients. The pathologic response was evaluated according to the tumor regression grade (TRG). The prognostic role of pathologic response in recurrence-free survival (RFS) and overall survival (OS) was assessed using Kaplan–Meier curves with the log-rank test and multivariate Cox models. Factors that had potential influence on pathologic response were also analyzed using multivariate logistic regression and Kruskal–Wallis/Mann–Whitney U tests.
Patients whose tumors achieved pathologic response after preoperative chemotherapy had significant longer RFS and OS than patients whose tumor had no pathologic response to chemotherapy (median RFS: 9.9 vs. 6.5 months, P = 0.009; median OS: 40.7 vs. 28.1 months, P = 0.040). Multivariate logistic regression and Kruskal–Wallis/Mann–Whitney U tests showed that metastases with small diameter, metastases from the left-side primary tumors, and metastases from patients receiving long-duration chemotherapy had higher pathologic response rates than their control metastases (all P < 0.05). A decrease in the serum carcinoembryonic antigen (CEA) level after preoperative chemotherapy predicted an increased pathologic response rate (P < 0.05). Although the application of targeted therapy did not significantly influence TRG scores of all cases of metastases, the addition of cetuximab to chemotherapy resulted in a higher pathologic response rate when combined with irinotecan-based regimens rather than with oxaliplatin-based regimens.
We found that the evaluation of pathologic response may predict the prognosis of Chinese colorectal cancer patients with liver metastases after preoperative chemotherapy. Small tumor diameter, long-duration chemotherapy, left primary tumor, and decreased serum CEA level after chemotherapy are associated with increased pathologic response rates.
- Colorectal cancer
- Liver metastases
- Pathologic response
Colorectal cancer is the fifth most common cancer and the leading cause of cancer-related death in China, with an increasing incidence of 4%–6% annually [1–4]. The liver is the most common organ for colorectal cancer metastases, and liver metastasis is the main cause of death of patients with colorectal cancer [5, 6]. Currently, surgical resection is the primary therapeutic strategy for patients with isolated liver metastases; it results in an improved clinical outcome, with a 5-year overall survival (OS) rate of 58% . The administration of chemotherapy before surgical resection has been shown to increase not only the curative resection rate for initially unresectable lesions but also the disease-free survival rate for patients with resectable disease [8–10]. Thus, preoperative chemotherapy followed by hepatectomy is recommended for colorectal cancer patients with liver metastases, especially for patients at high risk [9, 11–13].
Currently, the efficacy of preoperative chemotherapy is often evaluated based on the radiologic response, according to Response Evaluation Criteria in Solid Tumors (RECIST) , using computed tomography or magnetic resonance imaging (MRI). However, prolonged survival is not always associated with radiologic response, especially when targeted therapy agents are added to the chemotherapy regimen . Pathologic response is another evaluation index that could be used to evaluate the efficacy of preoperative chemotherapy. The pathologic response of colorectal cancer patients with liver metastases is generally evaluated according to the tumor regression grade (TRG) . Rubbia-Brandt et al.  reported an association between the pathologic response and OS in colorectal cancer patients with resected liver metastases, which was confirmed by Blazer et al. , who suggested that the pathologic response might be used as a new outcome endpoint after surgical resection of liver colorectal metastases. Additionally, the pathologic response is also regarded as a predictive factor for survival in patients with other metastatic diseases, including metastatic breast cancer , gastric cancer , esophageal cancer [20, 21], and pancreatic cancer , who receive preoperative chemotherapy or radiotherapy. Several studies have attempted to determine factors that might be associated with pathologic response, such as the duration of preoperative chemotherapy and the combination of bevacizumab and preoperative traditional chemotherapy [23–26]. However, the number of cases in these studies was relatively small, and to date no data obtained in studies of Chinese patients have been reported.
In this retrospective study, we analyzed the metastatic lesions that were resected from colorectal cancer patients with liver metastases. We aimed to demonstrate the association between the pathologic response to pre-hepatectomy chemotherapy and prognosis in colorectal cancer patients with liver metastases. We also analyzed factors that might have a potential effect on TRG.
This retrospective study was performed at Sun Yat-sen University Cancer Center in Guangzhou, China. All patients who were consecutively diagnosed with colorectal cancer and liver metastases and therefore underwent hepatectomy after preoperative chemotherapy between June 2002 and December 2015 were included. Inclusion criteria were as follows: (1) pathologic diagnosis of colorectal cancer with liver metastases; (2) preoperative fluorouracil-based chemotherapy as a first/second-line treatment; and (3) adequate metastasis specimens for analysis. Patients with extrahepatic metastases and those who underwent a prior hepatectomy were excluded. This study was approved by the Ethical Review Board of Sun Yat-sen University Cancer Center. Informed consent was waived given the study’s non-interventional retrospective design. The authenticity of this article was validated by uploading the key raw data to the Research Data Deposit public platform (http://www.researchdata.org.cn), with Approval Number RDDA2017000150.
Pathologic response assessment
Follow-up was performed until August 2016. Dates of relapse and death were verified by hospital records or by phone contact with the patients or their relatives. Radiologic responses were evaluated by computed tomograph or MRI according to RECIST version 1.1 . The responses were then classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) . Other clinicopathologic information that was collected from patient records included age, sex, primary tumor location, and level of preoperative carcinoembryonic antigen (CEA). The TNM stage of the tumors was reclassified according to the Union for International Cancer Control TNM Staging System (7th edition). Metastases were grouped into small-size tumor (diameter < 2.5 cm) and large-size tumor (diameter ≥ 2.5 cm). Short duration of preoperative chemotherapy was defined as ≤ 4 cycles for 2-week regimens or ≤ 3 cycles for 3-week regimens, whereas long duration of preoperative chemotherapy was defined as > 4 cycles for 2-week regimens or > 3 cycles for 3-week regimens.
Kaplan–Meier curves with log-rank tests were used to compare the RFS and OS rates in different TRG levels. RFS was defined as the date of hepatectomy to the date of the first relapse at any site or death from any cause without relapse; the patients who were lost during follow-up or still alive or relapse-free at the last follow-up were censored. OS was calculated from hepatectomy to death from any cause; the patients who were lost during follow-up or still alive at the last follow-up were censored. A multivariate logistic regression was performed as a preliminary screen for potential factors associated with TRG. Kruskal–Wallis or Mann–Whitney U tests were used to further compare the pathologic response rates between different parameters, including tumor size, duration of preoperative chemotherapy, preoperative CEA level, primary tumor site, and different combinations of chemotherapy regimens. All the statistical analyses were performed using SPSS software version 22.0 (Chicago, IL, USA) with two-tailed tests. A P value of < 0.05 was considered statistically significance.
Clinicopathologic characteristics of colorectal cancer patients with liver metastases according to preoperative chemotherapy
Non-targeted therapy (n = 114)
Bev-combined therapy (n = 22)
Cet-combined therapy (n = 23)
Primary tumor site
Primary tumor grade
Primary tumor pT categorya
Primary tumor pN categorya
Preoperative CEA level
≤ 5 ng/mL
> 5 ng/mL
Number of metastases per patientb
Resection status of liver metastases
Cycles of preoperative chemotherapyb
Duration of preoperative chemotherapyc
Oxa + Iri-based
Clinicopathologic characteristics of patients based on liver metastatic tumors
Primary tumor site
Primary tumor grade
Histological subtype of primary tumor
Primary tumor pT categorya
Primary tumor pN categorya
Size of metastases (cm)
Resection status of liver metastases
Duration of preoperative chemotherapyc
Oxa + Iri-based
Survival predictive value of the pathologic response
Predictive factors for survival by multivariate Cox analysis
HR (95% CI)
HR (95% CI)
Age (> 65 vs. ≤ 65 years)
Primary tumor site (left vs. right)
Tumor grade (G3 vs. G1–2)
pT category (pT3–4 vs. pT1–2)
pN category (pN1–2 vs. pN0)
Preoperative CEA level (> 5 vs. ≤ 5 ng/mL)
Interval from primary tumor resection to liver metastases (> 12 vs. ≤ 12 months)
Number of metastases (> 1 vs. 1 per patient)
Maximum size of metastases (> 5 vs. ≤ 5 cm)
Resection status (R1–2 vs. R0)
Radiologic response (SD/PD vs. PR)a
Duration of preoperative chemotherapy (long vs. short)b
Chemotherapy backbone (CT with Bev vs. CT only)
Chemotherapy backbone (CT with Cet vs. CT only)
Postoperative chemotherapy (yes vs. no)
TRG (TRG4–5 vs. TRG1–3)c
Factors and their influence on the TRG
Multivariable logistic analyses of potential benefit factors for pathologic response in terms of tumor-related analysis
OR (95% CI)
Age (> 65 vs. ≤ 65 years)
Primary tumor site (left vs. right)
pN category (pN1-2 vs. pN0)
CEA decline (yes vs. no)a
Metastases presentation (metachronous vs. synchronous)
Size of metastases (< 2.5 vs. ≥ 2.5 cm)
Resection status (R1–2 vs. R0)
Preoperative chemotherapy backbone (CT with Bev vs. CT only)
Preoperative chemotherapy backbone (CT with Cet vs. CT only)
Duration of preoperative chemotherapy (long vs. short)
Duration of preoperative chemotherapy was also found to be associated with TRG. Of the 380 metastases, 282 (74.2%) were resected from 113 patients who received 2-week regimens (short duration: 112 metastases from 50 patients; long duration: 170 from 63 patients), and 98 (25.8%) were resected from 46 patients who received 3-week regimens (short duration: 51 metastases from 19 patients; long duration: 47 metastases from 27 patients). The metastases from patients with long-duration chemotherapy had significantly higher pathologic response rate than those from patients with short-duration chemotherapy (TRG1–2 48.8% and TRG3 37.8% vs. TRG1–2 25.8% and TRG3 38.0%, P < 0.001; Fig. 3b).
The serum CEA levels before preoperative chemotherapy were not recorded for 30 patients with 85 metastases in this study. Of the remaining 295 metastases, 226 (76.6%) were from the patients who presented a serum CEA decline after chemotherapy, whereas 69 (23.4%) were from the patients who showed no decrease in the serum CEA level. Moreover, 182 (80.5%) of 226 metastases from the patients with CEA decline were classified as TRG1–2 or TRG3; the metastases from patients who presented CEA decline had significantly higher pathologic response rate than those from patients who did not show serum CEA decline (TRG1–2 46.0% and TRG3 34.5% vs. TRG1–2 18.8% and TRG3 42.0%, P < 0.001, Fig. 3c).
An abundance of evidence indicated the association between primary tumor site of metastatic colorectal cancer and radiologic response to chemotherapy. As far as pathologic response was concerned, 67 metastases (17.6%) were from 29 patients with primary tumors on the right side, whereas 313 (82.4%) metastases were from 130 patients with primary tumors on the left side. Metastases from patients with left-side primary tumors had significantly higher pathologic response rate than those from patients with right-side primary tumors (TRG1–2 41.2% and TRG3 38.3% vs. TRG1–2 28.4% and TRG3 35.8%, P = 0.008; Fig. 3d).
Different chemotherapy regimens were considered factors that might influence TRG. Of the three groups of chemotherapy regimens, chemotherapy administered with or without targeted therapy did not show a significant difference in the pathologic response rates (TRG1–2 64.2% and TRG3 14.2% vs. TRG1–2 67.4% and TRG3 10.4% vs. TRG1–2 68.2% and TRG3 9.1%, for the non-targeted, bevacizumab-combined, and cetuximab-combined therapy groups, respectively, P = 0.442). However, for metastases from the patients treated with cytotoxic chemotherapy alone (non-targeted therapy), the metastases from patients with the oxaliplatin-based chemotherapy showed higher pathologic response rate than those from patients with the irinotecan-based chemotherapy (TRG1–2 44.0% and TRG3 33.7% vs. TRG1–2 13.5% and TRG3 55.8%, P = 0.001). For metastases from patients treated with cytotoxic chemotherapy in combination with bevacizumab (bevacizumab-combined therapy), the metastases from patients in the oxaliplatin-based group had higher pathologic response rate than those from patients in the irinotecan-based group, but the difference was not statistically significant (TRG1–2 44.8% and TRG3 41.4% vs. TRG1–2 53.3%, TRG3: 20.0%, P = 0.989). Of the 82 metastases from patients treated with chemotherapy in combination with cetuximab (cetuximab-combined therapy), the metastases from patients receiving irinotecan-based chemotherapy presented higher pathologic response rate than those from patients receiving oxaliplatin-based chemotherapy (TRG1–2 43.9% and TRG3 42.4% vs. TRG1–2 12.5% and TRG3 18.8%, P < 0.001; Fig. 3e). In metastases from patients who were treated with oxaliplatin-based chemotherapy, those from patients undergoing oxaliplatin/cetuximab therapy presented lower pathologic response rate than those from patients undergoing oxaliplatin-based chemotherapy alone or bevacizumab/oxaliplatin combined therapy (TRG1–2 12.5% and TRG3 18.8% vs. TRG1–2 44.0% and TRG3 33.7% vs. TRG1–2 44.8% and TRG3 41.4%, P = 0.001; Fig. 3e). Among metastases from those patients undergoing irinotecan-based chemotherapy, the addition of either bevacizumab or cetuximab led to higher pathologic response rate than chemotherapy alone (TRG1–2 53.3% and TRG3 20.0% or TRG1–2 43.9% and TRG3 42.4% vs. TRG1–2 13.5% and TRG3 55.8%, P = 0.048 or < 0.001; Fig. 3e).
In this retrospective cohort study, we showed that the pathologic response after preoperative chemotherapy could predict RFS and OS in a cohort of Chinese colorectal cancer patients with liver metastases who also underwent hepatectomy. Our results supported the results in Western populations [17, 24]. Klinger et al.  found that, after liver resection, a favorable TRG score was significantly associated with extended progression-free survival and OS. Moreover, Blazer et al.  suggested that pathologic response could be used as a new outcome endpoint for colorectal cancer patients with liver metastases who undergo hepatectomy, because pathologic response strongly predicts postoperative survival.
Blazer et al.  also reported that metastases with small size and a preoperative normal CEA level predicted improved pathologic response. Similarly, we found that, in a Chinese patient cohort, metastases with small size were an independent predictor of pathologic response. We also found that a decrease in serum CEA levels after preoperative chemotherapy was another independent predictor of pathologic response. To date, the optimal duration of preoperative chemotherapy remains unknown; to our knowledge, few studies have focused on this issue. Kishi et al.  suggested that extended preoperative chemotherapy was associated with an increased risk of liver insufficiency after surgery, but the pathologic response rate was not improved. However, in the present study, we found that long-duration chemotherapy was an independent predictor of pathologic response. This discordance is probably because of different definitions of long-duration chemotherapy. Kishi et al.  used a cutoff of 8 cycles to distinguish short-duration from long-duration chemotherapy. However, in the present study, we defined long-duration chemotherapy as longer than 4 cycles for patients who received 2-week regimens and 3 cycles for patients who received 3-week regimens. By this definition, we suggested that a too-short duration of preoperative chemotherapy (< 2.0 months) might not result in satisfactory tumor pathologic regression. In terms of the primary tumor site, this finding was consistent with those of previous studies that found that metastases from the left-side primary tumors had a relatively better response to chemotherapy, as well as to targeted therapy, than metastases from the right-side primary tumors [27–29]. This may due to the genetic heterogeneity of primary tumors on different sides. However, the small sample size, especially for tumors on the right side, indicates that interpretations should be made with caution.
The influence of preoperative chemotherapy in combination with targeted therapy on pathologic response is another source of debate. In the present study, the addition of bevacizumab or cetuximab did not result in a significant difference in pathologic response rates for the whole metastases cohort, but these drugs did have an effect when certain chemotherapy backbones were implemented. These results were in agreement with those of most studies that found that the addition of targeted therapy, including bevacizumab and cetuximab, probably has an effect on the pathologic response of colorectal cancer and liver metastases; however, the effect depended on the chemotherapy backbone [17, 25, 26, 30]. In the present study, for metastases treated with irinotecan-based chemotherapy, the addition of either bevacizumab or cetuximab resulted in higher pathologic response rates than chemotherapy alone. This confirmed the finding of Carrasco et al.  that anti-epidermal growth factor receptor agents combined with irinotecan-based regimens were associated with higher pathologic response rates and further supplemented the advantage of bevacizumab/irinotecan-based regimens. In contrast, for metastases treated with oxaliplatin-based chemotherapy, the addition of bevacizumab led to a pathologic response rate similar to that in the chemotherapy-alone subgroup but led to a higher pathologic response rate than that in the cetuximab-combined chemotherapy subgroup. This result was in accordance with the results found in the cetuximab subgroup, in which cetuximab/irinotecan-based chemotherapy resulted in a higher pathologic response rate than the cetuximab/oxaliplatin-based combination. This finding is also supported by previously reported results that cetuximab/oxaliplatin-based regimens were probably not a good choice in terms of pathologic response rate for the treatment of colorectal cancer with liver metastases [25, 26]. However, considering the relatively small sample sizes of the targeted therapy groups in the present study, the results should be interpreted with caution. Additionally, we found that in both the non-targeted therapy and bevacizumab-combined therapy groups, oxaliplatin-based chemotherapy seemed to result in a higher pathologic response rate than irinotecan-based regimens, even though the advantage seen in the bevacizumab subgroup was only a tendency. Carrasco et al.  had a similar finding, even though the result did not reach statistical significance in the subgroup that received cytotoxic drugs alone. However, because of the retrospective design and relatively small sample size of these studies, the optimal combination regimen is still unknown. In addition, in the present study, Kras status was not recorded for most patients; thus, the association between Kras status and pathologic response was not evaluated. Furthermore, in the present study, interobserver variability in terms of the pathologic response and the confounding of resectable/potentially resectable cases may have led to bias. Therefore, prospective randomized trials are needed.
We found that pathologic response was significantly associated with longer survival after liver resection in colorectal cancer patients with liver metastases. Metastases with a small size, left-side primary tumor, a decrease in the serum CEA level after preoperative chemotherapy, and long-duration chemotherapy might predict high pathologic response rates. However, the optimal combination regimen still needs to be investigated.
RHX and YHL participated in the Study design. YW, YFY, HCL, BKL, FHW, ZQW, PRD, GC, XJW, ZHL, ZZP, DSW, PS, and SMY participated in the data collection and processing. YW and HCL conducted the statistical analysis and drafting. All authors read and approved the final manuscript.
Our gratitude is expressed to all the patients for the participation in this study. We also appreciate all colleagues in Sun Yat-sen University Cancer Center, who have participated in performing the treatment in the current study. Medbanks (Beijing) Network Technology Co., Ltd was thanked for data collection.
The authors declare that they have no competing interests.
No funding was received.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dai Z, Zheng RS, Zou XN, et al. Analysis and prediction of colorectal cancer incidence trend in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46(7):598–603.PubMedGoogle Scholar
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.View ArticlePubMedGoogle Scholar
- Liu S, Zheng R, Zhang M, et al. Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res. 2015;27(1):22–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang ZQ, Zhang DS, Xu N, et al. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chin J Cancer. 2016;35:8.View ArticlePubMedPubMed CentralGoogle Scholar
- Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.View ArticlePubMedGoogle Scholar
- Lin GN, Liu PP, Liu DY, et al. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy. Chin J Cancer. 2016;35:5.View ArticlePubMedPubMed CentralGoogle Scholar
- Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–64.View ArticlePubMedPubMed CentralGoogle Scholar
- Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28(13):2300–9.View ArticlePubMedGoogle Scholar
- Ihnat P, Vavra P, Zonca P. Treatment strategies for colorectal carcinoma with synchronous liver metastases: which way to go? World J Gastroenterol. 2015;21(22):7014–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.View ArticlePubMedGoogle Scholar
- Brandi G, De Lorenzo S, Nannini M, et al. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol. 2016;22(2):519–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.View ArticlePubMedGoogle Scholar
- Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.View ArticlePubMedGoogle Scholar
- Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304.View ArticlePubMedGoogle Scholar
- Blazer DR, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.View ArticlePubMedGoogle Scholar
- Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–9.View ArticlePubMedGoogle Scholar
- Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80.View ArticlePubMedGoogle Scholar
- Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer-am Cancer Soc. 1994;73(11):2680–6.Google Scholar
- Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241(5):810–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Chun YS, Cooper HS, Cohen SJ, et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol. 2011;18(13):3601–7.View ArticlePubMedGoogle Scholar
- Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17(11):2870–6.View ArticlePubMedGoogle Scholar
- Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17(8):2059–65.View ArticlePubMedGoogle Scholar
- Carrasco J, Gizzi M, Pairet G, et al. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Br J Cancer. 2015;113(9):1298–304.View ArticlePubMedPubMed CentralGoogle Scholar
- Stremitzer S, Stift J, Singh J, et al. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. Eur J Surg Oncol. 2015;41(7):868–74.View ArticlePubMedGoogle Scholar
- Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.View ArticlePubMedGoogle Scholar
- Sunakawa Y, Ichikawa W, Tsuji A, et al. Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials. Clin Colorectal Cancer. 2016;16(3):e171–80.View ArticlePubMedGoogle Scholar
- Wang F, Bai L, Liu TS, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34(9):384–93.PubMedGoogle Scholar
- Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21(4):309–15.View ArticlePubMedGoogle Scholar